A retrospective, observational study from US and UK databases showed that in T2D patients inadequately controlled on oral glucose-lowering drugs, initiation of first injectable therapy (GLP1 RA or BI) did not occur until HbA1c was considerably above target, when control was harder to achieve [28]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.